title: Effects of alfuzosin with methylprednisolone for spontaneous expulsion and pain control of lower ureteral stone.
abstract: The aim of this study is to evaluate the efficacy of alfuzosin with methylprednisolone on expulsion and pain control of lower ureteral stones <10 mm in size. Between June 2005 and June 2007, 113 patients with lower ureteral stones <10 mm in size were enrolled in the study. The patients were divided into a control group (group I) and medical expulsive therapy group (group II). Group I (n = 66) received oral analgesics daily and group II (n = 47) received the same analgesics along with 10 mg alfuzosin and 8 mg methylprednisolone for 4 weeks orally once a day. The treatment was continued until stone expulsion or to a maximum of 4 weeks. All patients were allowed 25 mg pethidine hydrochloride intramuscular injections if needed for suboptimal pain control. The average stone size was 6.15 mm in group I and 5.42 mm in group II. Of the 113 patients, 80 became stone free (70.7%). Group II had significantly higher stone free rates (82.9 vs. 62.1%, p = 0.014), fewer expulsion times (mean 4.4 vs. 7.3 days, p = 0.001), and mean number of intramuscular analgesic injections (0.8 vs. 2.1) compared to group I. Alfuzosin with methylprednisolone treatment seems safe and effective for lower ureteral stones <10 mm in size as demonstrated by the increased stone free rate, earlier expulsion, and reduced additional analgesic therapy.
authors.affiliation: Department of Urology, Chonnam National University Medical School, Gwangju, Republic of Korea.
authors.forename: Eu Chang
authors.initials: EC
authors.lastname: Hwang
authors.forename: In Sang
authors.initials: IS
authors.lastname: Hwang
authors.forename: Ho Song
authors.initials: HS
authors.lastname: Yu
authors.forename: Sun-Ouck
authors.initials: SO
authors.lastname: Kim
authors.forename: Seung Il
authors.initials: SI
authors.lastname: Jung
authors.forename: Taek Won
authors.initials: TW
authors.lastname: Kang
authors.forename: Dong Deuk
authors.initials: DD
authors.lastname: Kwon
authors.forename: Kwangsung
authors.initials: K
authors.lastname: Park
authors.forename: Soo Bang
authors.initials: SB
authors.lastname: Ryu
authors.forename: Myung Ki
authors.initials: MK
authors.lastname: Kim
authors.forename: Ji Wan
authors.initials: JW
authors.lastname: Lu
mesh_terms: D000293:Adolescent; D058668:Adrenergic alpha-1 Receptor Antagonists / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy*; D011799:Quinazolines / Q000008:administration & dosage* / Q000009:adverse effects; D014514:Ureteral Calculi / Q000628:therapy*
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D011799:Quinazolines; C047638:alfuzosin; D008775:Methylprednisolone